Infections 10

Topic: Imaging

Created on Monday, February 11 2013 by gliageek

Last modified on Monday, February 11 2013.

 
        A) Rituximab
 
        B) Methotrexate
 
        C) Solid organ transplantation
 
        D) Ionizing radiation
 
        E) Natlazumab
 

 

	= Go back to the top of the page.
	= Reload a different version of this question ().
	= Load a random question from the database.
	= Use this question as a template to create a totally NEW question.
	= Enter detailed rating for this question!
Average rating not yet available	= How users like you have rated this question.

This question was created on February 11, 2013 by gliageek.
This question was last modified on February 11, 2013.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANSWERS AND EXPLANATIONS

---

A) Rituximab

This answer is incorrect.

Progressive Multifocal Leukoencephalopathy has rarely been reported in association with Rituximab therapy.  (See References)

					Average rating not yet available
Please log in if you want to rate questions.

 

 

 

 

 

 

 

 

 

---

B) Methotrexate

This answer is incorrect.

Methotrexate therapy may be associated with a noninflammatory necrotizing leukoencephalopathy.  (See References)

					Average rating not yet available
Please log in if you want to rate questions.

 

 

 

 

 

 

 

 

 

---

C) Solid organ transplantation

This answer is incorrect.

So far, no cases of progressive multifocal leukoencephalopathy have been reported in solid organ transplant recipients.  (See References)

					Average rating not yet available
Please log in if you want to rate questions.

 

 

 

 

 

 

 

 

 

---

D) Ionizing radiation

This answer is incorrect.

Radiation therapy may be associated with a noninflammatory necrotizing leukoencephalopathy.  (See References)

					Average rating not yet available
Please log in if you want to rate questions.

 

 

 

 

 

 

 

 

 

---

E) Natlazumab

This answer is correct.

The incidence of Progressive Multifocal Leukoencephalopathy in patients receiving Natalizumab for multiple sclerosis is approximately 200 per 100,000 person years. No cases have been reported in multiple sclerosis patients not receiving this therapy.  (See References)

					Average rating not yet available
Please log in if you want to rate questions.

 

 

 

 

References:

1. Boster, A.L., Nicholas, J.A., Topalli, I., Kisanuki, Y.Y., Pei, W., Morgan-Followell, B., Kirsch, C.F., Racke, M.K., and Pitt, D. (2013). "Lessons Learned From Fatal Progressive Multifocal Leukoencephalopathy in a Patient With Multiple Sclerosis Treated With Natalizumab." JAMA Neurol 1-5. (PMID:23338729)
2. Steiner, I., and Berger, J.R. (2012). "Update on progressive multifocal leukoencephalopathy." Curr Neurol Neurosci Rep, 12(6) 680-6. (PMID:22991070)
3. Gheuens, S., Wüthrich, C., and Koralnik, I.J. (2013). "Progressive multifocal leukoencephalopathy: why gray and white matter." Annu Rev Pathol, 8 189-215. (PMID:23092189)

					Average rating not yet available
Please log in if you want to rate questions.

 

FrontalCortex.com -- Neurology Review Questions -- Neurology Boards -- Board Review -- Residency Inservice Training Exam -- RITE Exam Review
imaging
Infections 10
Question ID: 021113111
Question written by gliageek. (C) FrontalCortex.com 2006-2009, all rights reserved. Created: 02/11/2013
Modified: 02/11/2013
Estimated Permutations: 120